Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study Evaluating Treatment With Oral Navelbine [vinorelbine] and Cisplatin Administered Weekly and Concomitant Radiotherapy in Elderly Patients With no Operable NSCLC.

Trial Profile

Phase II Study Evaluating Treatment With Oral Navelbine [vinorelbine] and Cisplatin Administered Weekly and Concomitant Radiotherapy in Elderly Patients With no Operable NSCLC.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Vinorelbine (Primary)
  • Indications Adenocarcinoma; Carcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms RACCOSA
  • Most Recent Events

    • 05 Jun 2018 Results evaluating the ability of a comprehensive geriatric assessment (CGA) to select the elderly La-NSCLC patients who potentially may benefit from concurrent radio-chemotherapy presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 01 May 2018 Status changed from active, no longer recruiting to completed.
    • 09 Mar 2015 Planned End Date changed from 1 Jan 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top